1 – 10 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Reevaluating the Definition of Clinically Significant Prostate Cancer as Grade Groups 2 to 5 : An Imperative for Improved Risk Stratification
2024) In Journal of Urology(
- Contribution to journal › Article
- 2021
-
Mark
Identification of a serum biomarker signature associated with metastatic prostate cancer
(
- Contribution to journal › Article
-
Mark
Placebo comparator group selection and use in surgical trials : The aspire project including expert workshop
(
- Contribution to journal › Article
- 2020
-
Mark
Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines)
(
- Contribution to journal › Scientific review
- 2019
-
Mark
Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy
(
- Contribution to journal › Article
- 2018
-
Mark
Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model : An Individual Patient Data Meta-Analysis
(
- Contribution to journal › Article
- 2017
-
Mark
Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone : Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above
(
- Contribution to journal › Article
- 2016
-
Mark
The profile feasibility study : Targeted screening of men with a family history of prostate cancer
(
- Contribution to journal › Article
- 2015
-
Mark
Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study.
(
- Contribution to journal › Article
-
Mark
Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer.
2015) In Oncotarget(
- Contribution to journal › Article